Fwd: CRs forward this to your class even while people are in the vacation mood.

[AKSHAT SHARMA]

---------- Forwarded message ----------
From: Ashutosh Ojha <ashu...@gmail.com>
Date: Tue, Oct 25, 2011 at 10:01 PM
Subject: CRs forward this to your class even while people are in the vacation mood.
To: Jyothi Chaluvadi <jyoth...@yahoo.com>
Cc: aadeshc...@gmail.com, abhisr...@yahoo.com, akshat.p...@gmail.com, Nirmit Shah <nirmi...@gmail.com>, shaheen merchant <shahee...@gmail.com>, sneha ushir <sneha_...@yahoo.com>, ishan...@yahoo.co.in, rpb_...@yahoo.co.in, Priyanka Shah <priyan...@hotmail.com>, vedika Gulati <vedika...@yahoo.in>, Vivek Gupta <mrgupt...@yahoo.com>

All CRs reading this e-mail are requested to forward this to your classmates.

 

Dear Jyothi,

 

I acknowledge receipt of this e-mail from you as under:

 

"Thank you so much for sharing the Deloitte consultancy document with us.

I would like to bring to your notice a small error in the page no. 10 of the document.
The names of the last two diseases haven't been mentioned in the graphical representation of the changing disease profiles graphical representation.

Thank you.

Regards,
Jyothi Chaluvadi.
MBA-Pharm.Tech"

What an eagle eye you have! Well I owe you a clarification. The source quoted in the Deloitte presentation does not mention two of the last entries viz. accidents and acute infections. Typically the medical epidemiologists leave out references to morbidity and mortality resulting from accidents, wars, natural calamities etc. when they present such charts. You can further satisfy your curiosity by going to the CII McKinsey Paper sourced from Enam that appears in The Fortis Healthcare presentation. Just google for it.

 

But I must take this small exchange between you (Jyothi) and I public to make the following points:

 

• The CRs, despite being in a holiday mood have found time to forward a "serious" article to the class promptly.
• The "serious" student/s have made it a point to read the paper and even between the lines
• Jyothi actually questions data even from the Big 5 Consultant. Great attitude.   Keep it up. I am being congratulatory and not sarcastic.
• Did I hear some of you snigger and mutter under your breath? ...  "Why does this Prof (meaning, yours truly) does not go and get a life?" इस प्रोफेस्सर को और कोई काम नहीं है क्या?
• Well if watching India white wash (Brownwash if you please), England 5-0 in the cricket ODIs as I type this and that too with a thumping margin, is not having a great life, what is? And now I am off to watch a night show next door.

Life is good.

 

Cheers and a Happy Diwali to you and your loved ones!

 

Best wishes,

 

Ashutosh Ojha

 

On Sun, Oct 23, 2011 at 2:13 PM, Ashutosh Ojha <ashu...@gmail.com> wrote:

Dear Class of MPharm+MBA Pharmatech and Healthcare,

 

Sorry to intrude into your well deserved Diwali break. But I thought I will reach some wonderful reading material to you so that at least some of you who volunteered to make your presentations to the class soon after the Diwali break, will have some additional material at your disposal to work with.

 

The Big 5 Consulting Companies from time to time, take out, what are referred to as "white papers". My younger sister's son (bhanja viz. nephew) works in one of these Big 5 after his Chemical Engineering and an MBA from one of the IIMs. He is with Deloitte since the last 2 years. Some months back he approached me on behalf of Deloitte to pick my brains (did I say "brains"?  ) about my views on the Indian Pharmaceutical Industry.

 

After some initial resistance I agreed to be a part of their tele-conferencing interview in which my bhanja's colleagues from the US office, Singapore office and Mumbai and Hyderabad offices simultaneously grilled me for an hour. Of course they also must have talked to many more experts from the Pharma industry to come out with this and other "white papers." I put one condition though. I said they could use my views freely if they found any merit in them but as my "fees",  in future, they would share with me their "white papers" on the Pharma and Healthcare sector free of charge.

 

My bhanja and Deloitte have kept up their promise. They have shared with me a "white paper" presented by the head of Deloitte India at some conference in Ireland exactly a month back. I think the paper is very useful and informative. You may want to skip the Ireland references as it is not relevant to our Syllabus and the assignments coming up.

 

I have also shared with Nirmit Shah, (MPharm+MBA, 1st year, Pharma Analysis) a  hard copy of a somewhat older McKinsey "white paper" which is also extremely well written. You may want to write to Nirmit at nirmi...@gmail.com to lay your hands on a copy of the paper which at the very least will cost you photocopying charges.

 

The mail below from my bhanja and the file attachment is self explanatory.

 

Wishing you happy holidays.

 

Ashutosh Ojha 

 

_________________________________________________________________

Hi Mamaji,

Attaching the latest presentation on the pharma sector. This was presented by the head of Deloitte India to a conference in Ireland. It has a structure which I think your MBA students would appreciate.

Regards,

 

A